Geron(GERN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 & geron Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights U.S. commercial launch of RYTELO™ (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to or ineligible for etythropoiesisstimulating agents (ESAs), regardless of ring sideroblast (RS) status NCCN Guidelines® updated to include the use of RYTELO in both RS+ and RS- patients for second-line treatme ...